WO2011027289A1 - Chromone derivatives, a process for their preparation and their therapeutic applications - Google Patents
Chromone derivatives, a process for their preparation and their therapeutic applications Download PDFInfo
- Publication number
- WO2011027289A1 WO2011027289A1 PCT/IB2010/053895 IB2010053895W WO2011027289A1 WO 2011027289 A1 WO2011027289 A1 WO 2011027289A1 IB 2010053895 W IB2010053895 W IB 2010053895W WO 2011027289 A1 WO2011027289 A1 WO 2011027289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- piperazin
- butyl
- chromen
- oxo
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 150000004777 chromones Chemical class 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 21
- 230000008569 process Effects 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title description 9
- 239000003814 drug Substances 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 230000000926 neurological effect Effects 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 8
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims description 6
- 208000012661 Dyskinesia Diseases 0.000 claims description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 201000006517 essential tremor Diseases 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 235000015320 potassium carbonate Nutrition 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 150000002989 phenols Chemical class 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- OFNVYNPMZYWJOS-UHFFFAOYSA-N 6-hydroxy-3-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]chromen-4-one Chemical compound COc1ccccc1N1CCN(CCCCc2coc3ccc(O)cc3c2=O)CC1 OFNVYNPMZYWJOS-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- YUWURGJQXCUHGM-UHFFFAOYSA-N COCCS(O)(=O)=O.NC1=CC(N2CCN(CCCCC3=COC(C=C4OCOC4=C4)=C4C3=O)CC2)=CC=C1 Chemical compound COCCS(O)(=O)=O.NC1=CC(N2CCN(CCCCC3=COC(C=C4OCOC4=C4)=C4C3=O)CC2)=CC=C1 YUWURGJQXCUHGM-UHFFFAOYSA-N 0.000 claims 1
- VIWNWOYBBHTNGE-UHFFFAOYSA-N NC1=CC(N2CCN(CCCCC3=COC(C=C4OCOC4=C4)=C4C3=O)CC2)=CC=C1.O=C1C(C=C2OCOC2=C2)=C2OC=C1CCCCN(CC1)CCN1C1=C(C=CN2)C2=CC=C1 Chemical compound NC1=CC(N2CCN(CCCCC3=COC(C=C4OCOC4=C4)=C4C3=O)CC2)=CC=C1.O=C1C(C=C2OCOC2=C2)=C2OC=C1CCCCN(CC1)CCN1C1=C(C=CN2)C2=CC=C1 VIWNWOYBBHTNGE-UHFFFAOYSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 7
- 230000003291 dopaminomimetic effect Effects 0.000 abstract description 6
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 102000004073 Dopamine D3 Receptors Human genes 0.000 description 52
- 108090000525 Dopamine D3 Receptors Proteins 0.000 description 52
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 229910052681 coesite Inorganic materials 0.000 description 18
- 229910052906 cristobalite Inorganic materials 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 229910052682 stishovite Inorganic materials 0.000 description 18
- 229910052905 tridymite Inorganic materials 0.000 description 18
- 239000013078 crystal Substances 0.000 description 17
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 17
- 239000004031 partial agonist Substances 0.000 description 17
- 239000007836 KH2PO4 Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000005557 antagonist Substances 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 13
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 13
- 229960003638 dopamine Drugs 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- 239000000556 agonist Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- -1 heteroaryl phenylpiperazine butyl carboxamides Chemical class 0.000 description 11
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000164 antipsychotic agent Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 229940005529 antipsychotics Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical class C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- PKLOBBAMTDGEPV-UHFFFAOYSA-N 3-(4-bromobutyl)-6,7-dimethoxychromen-4-one Chemical compound O1C=C(CCCCBr)C(=O)C2=C1C=C(OC)C(OC)=C2 PKLOBBAMTDGEPV-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DKGJDNGJJYJBRY-UHFFFAOYSA-N 6-bromo-1-(2-hydroxy-4,5-dimethoxyphenyl)hexan-1-one Chemical compound COC1=CC(O)=C(C(=O)CCCCCBr)C=C1OC DKGJDNGJJYJBRY-UHFFFAOYSA-N 0.000 description 5
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- AGIQIOSHSMJYJP-UHFFFAOYSA-N 1,2,4-Trimethoxybenzene Chemical compound COC1=CC=C(OC)C(OC)=C1 AGIQIOSHSMJYJP-UHFFFAOYSA-N 0.000 description 4
- MPBCAMVRGKESAT-UHFFFAOYSA-N 3-[4-[4-(3-aminophenyl)piperazin-1-yl]butyl]-6,7-dimethoxychromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(N)=C1 MPBCAMVRGKESAT-UHFFFAOYSA-N 0.000 description 4
- HBPVGJGBRWIVSX-UHFFFAOYSA-N 6-bromohexanoyl chloride Chemical compound ClC(=O)CCCCCBr HBPVGJGBRWIVSX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- FASVANGGJBFZBO-UHFFFAOYSA-N 3-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]benzonitrile Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(C#N)=C1 FASVANGGJBFZBO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- OHBQPCCCRFSCAX-UHFFFAOYSA-N 1,4-Dimethoxybenzene Chemical compound COC1=CC=C(OC)C=C1 OHBQPCCCRFSCAX-UHFFFAOYSA-N 0.000 description 2
- LHHZRIYUOZPKSG-UHFFFAOYSA-N 1-(3-nitrophenyl)piperazine Chemical compound [O-][N+](=O)C1=CC=CC(N2CCNCC2)=C1 LHHZRIYUOZPKSG-UHFFFAOYSA-N 0.000 description 2
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 2
- UYRHOKSFOAHPEG-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]ethanesulfonamide Chemical compound COCCS(=O)(=O)NC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 UYRHOKSFOAHPEG-UHFFFAOYSA-N 0.000 description 2
- FBCZWQNVHNIQOD-UHFFFAOYSA-N 2-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC2=CC=CC=C2N1 FBCZWQNVHNIQOD-UHFFFAOYSA-N 0.000 description 2
- WSJIPKXCBHYDQZ-UHFFFAOYSA-N 3-[4-[4-(1H-benzimidazol-4-yl)piperazin-1-yl]butyl]-6,7-dimethoxychromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC2=C1N=CN2 WSJIPKXCBHYDQZ-UHFFFAOYSA-N 0.000 description 2
- KBKOCVFKHGIRRU-UHFFFAOYSA-N 3-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-6,7-dimethoxychromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl KBKOCVFKHGIRRU-UHFFFAOYSA-N 0.000 description 2
- AXFJTMDSTOEYHY-UHFFFAOYSA-N 4-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC2=C1NC(=O)N2 AXFJTMDSTOEYHY-UHFFFAOYSA-N 0.000 description 2
- ONCBZMAGCDDHES-UHFFFAOYSA-N 5-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2N(CC1)CCN1CCCCC1=COC(C=C(C(=C2)OC)OC)=C2C1=O ONCBZMAGCDDHES-UHFFFAOYSA-N 0.000 description 2
- CJHYAPNVFKSJOA-UHFFFAOYSA-N 5-piperazin-1-yl-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1N1CCNCC1 CJHYAPNVFKSJOA-UHFFFAOYSA-N 0.000 description 2
- PERRQVWGDUVTPH-UHFFFAOYSA-N 6,7-dimethoxy-3-[4-(4-pyridin-2-ylpiperazin-1-yl)butyl]chromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC=N1 PERRQVWGDUVTPH-UHFFFAOYSA-N 0.000 description 2
- WPKCRCCPRBRAAD-UHFFFAOYSA-N 6,7-dimethoxy-3-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]chromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=NC=CC=N1 WPKCRCCPRBRAAD-UHFFFAOYSA-N 0.000 description 2
- QWTRTWVVZBJIBK-UHFFFAOYSA-N 6,7-dimethoxy-3-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]chromen-4-one Chemical compound COC1=CC=CC=C1N1CCN(CCCCC=2C(C3=CC(OC)=C(OC)C=C3OC=2)=O)CC1 QWTRTWVVZBJIBK-UHFFFAOYSA-N 0.000 description 2
- VSSNBVJWGZWCBX-UHFFFAOYSA-N 6,7-dimethoxy-3-[4-[4-(3-nitrophenyl)piperazin-1-yl]butyl]chromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC([N+]([O-])=O)=C1 VSSNBVJWGZWCBX-UHFFFAOYSA-N 0.000 description 2
- FYLWVXTUYBRNIR-UHFFFAOYSA-N 6-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(6-hydroxy-1,3-benzodioxol-5-yl)hexan-1-one Chemical compound OC1=CC=2OCOC=2C=C1C(=O)CCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl FYLWVXTUYBRNIR-UHFFFAOYSA-N 0.000 description 2
- FGPSDSDJIBWPHR-UHFFFAOYSA-N 6-methoxy-3-[4-(4-phenylpiperazin-1-yl)butyl]chromen-4-one Chemical compound O=C1C2=CC(OC)=CC=C2OC=C1CCCCN(CC1)CCN1C1=CC=CC=C1 FGPSDSDJIBWPHR-UHFFFAOYSA-N 0.000 description 2
- KJISSGCXBACAIL-UHFFFAOYSA-N 6-methoxy-3-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]chromen-4-one Chemical compound O=C1C2=CC(OC)=CC=C2OC=C1CCCCN(CC1)CCN1C1=CC=CC=C1OC KJISSGCXBACAIL-UHFFFAOYSA-N 0.000 description 2
- DFCOBJYFUZVHPH-UHFFFAOYSA-N 6-methoxy-3-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]chromen-4-one Chemical compound O=C1C2=CC(OC)=CC=C2OC=C1CCCCN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 DFCOBJYFUZVHPH-UHFFFAOYSA-N 0.000 description 2
- GSGUNVZOPJOSJO-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-6-methyl-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound CC=1OC2=CC=3OCOC=3C=C2C(=O)C=1CCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl GSGUNVZOPJOSJO-UHFFFAOYSA-N 0.000 description 2
- IRNJIZSWJGGXDW-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound ClC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1Cl IRNJIZSWJGGXDW-UHFFFAOYSA-N 0.000 description 2
- HDTLDVMZMBPLRH-UHFFFAOYSA-N 7-[4-[4-(2,3-difluorophenyl)piperazin-1-yl]butyl]-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound FC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1F HDTLDVMZMBPLRH-UHFFFAOYSA-N 0.000 description 2
- MSAZDJCWBLKZSX-UHFFFAOYSA-N 7-[4-[4-(3-aminophenyl)piperazin-1-yl]butyl]-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound NC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 MSAZDJCWBLKZSX-UHFFFAOYSA-N 0.000 description 2
- YHOQRBNBPLLWFO-UHFFFAOYSA-N 7-[4-[4-(3-nitrophenyl)piperazin-1-yl]butyl]-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound [O-][N+](=O)C1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 YHOQRBNBPLLWFO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101150097070 Drd3 gene Proteins 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- FBFLJFZDYZOFGN-UHFFFAOYSA-N methyl n-[3-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]phenyl]carbamate Chemical compound COC(=O)NC1=CC=CC(N2CCN(CCCCC=3C(C4=CC(OC)=C(OC)C=C4OC=3)=O)CC2)=C1 FBFLJFZDYZOFGN-UHFFFAOYSA-N 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- HGLXDHSBXBBHGJ-UHFFFAOYSA-N n-[3-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]phenyl]acetamide Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(NC(C)=O)=C1 HGLXDHSBXBBHGJ-UHFFFAOYSA-N 0.000 description 2
- ASFVVBXQJQWDPY-UHFFFAOYSA-N n-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 ASFVVBXQJQWDPY-UHFFFAOYSA-N 0.000 description 2
- KLOYLPZTHLSRRB-UHFFFAOYSA-N n-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 KLOYLPZTHLSRRB-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FBZVZUSVGKOWHG-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylethanamine Chemical compound COC(C)(OC)N(C)C FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 1
- XJPVUJYLKOZVMH-UHFFFAOYSA-N 1-(2,3-difluorophenyl)piperazine Chemical compound FC1=CC=CC(N2CCNCC2)=C1F XJPVUJYLKOZVMH-UHFFFAOYSA-N 0.000 description 1
- CMCSPBOWEYUGHB-UHFFFAOYSA-N 1-(2,4-difluorophenyl)piperazine Chemical compound FC1=CC(F)=CC=C1N1CCNCC1 CMCSPBOWEYUGHB-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- ZJEZOZLPZKUZRE-UHFFFAOYSA-N 1-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]ethenesulfonamide Chemical compound NS(=O)(=O)C(=C)C1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 ZJEZOZLPZKUZRE-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FRDSHBSDCKKLPI-UHFFFAOYSA-N 2-(dimethylamino)-n-[3-[4-[4-(8-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)butyl]piperazin-1-yl]phenyl]ethanesulfonamide Chemical compound CN(C)CCS(=O)(=O)NC1=CC=CC(N2CCN(CCCCC=3C(C4=CC=5OCOC=5C=C4OC=3)=O)CC2)=C1 FRDSHBSDCKKLPI-UHFFFAOYSA-N 0.000 description 1
- YSOMKNSPOJDDKX-UHFFFAOYSA-N 2-(dimethylamino)ethanesulfonamide Chemical compound CN(C)CCS(N)(=O)=O YSOMKNSPOJDDKX-UHFFFAOYSA-N 0.000 description 1
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 1
- DFZIJAGHWXOSDA-UHFFFAOYSA-N 2-methoxychromen-4-one Chemical class C1=CC=C2OC(OC)=CC(=O)C2=C1 DFZIJAGHWXOSDA-UHFFFAOYSA-N 0.000 description 1
- CLPQSNXTFZZLHB-UHFFFAOYSA-N 2-methoxyethanesulfonamide Chemical group COCCS(N)(=O)=O CLPQSNXTFZZLHB-UHFFFAOYSA-N 0.000 description 1
- GKEDZBGZXKTTDZ-UHFFFAOYSA-N 2-piperazin-2-ylpyrimidine Chemical compound C1NCCNC1C1=NC=CC=N1 GKEDZBGZXKTTDZ-UHFFFAOYSA-N 0.000 description 1
- UGHMAQBZWONQLH-UHFFFAOYSA-N 2-pyridin-2-ylpiperazine Chemical compound C1NCCNC1C1=CC=CC=N1 UGHMAQBZWONQLH-UHFFFAOYSA-N 0.000 description 1
- JIGGCYGJVLLBDQ-UHFFFAOYSA-N 3-(4-tert-butylphenoxy)-7-hydroxy-8-[(4-methylpiperazin-1-yl)methyl]-2-(trifluoromethyl)chromen-4-one Chemical compound C1CN(C)CCN1CC1=C(O)C=CC(C2=O)=C1OC(C(F)(F)F)=C2OC1=CC=C(C(C)(C)C)C=C1 JIGGCYGJVLLBDQ-UHFFFAOYSA-N 0.000 description 1
- KUHCEKXEYYPAAU-UHFFFAOYSA-N 3-[4-[4-(1h-indol-4-yl)piperazin-1-yl]butyl]-6,7-dimethoxychromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC2=C1C=CN2 KUHCEKXEYYPAAU-UHFFFAOYSA-N 0.000 description 1
- RKACYXRXHZIHAM-UHFFFAOYSA-N 3-[4-[4-(2,3-difluorophenyl)piperazin-1-yl]butyl]-6,7-dimethoxychromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(F)=C1F RKACYXRXHZIHAM-UHFFFAOYSA-N 0.000 description 1
- PRIMEGXXBMBQFZ-UHFFFAOYSA-N 3-[4-[4-(3-hydroxyphenyl)piperazin-1-yl]butyl]-6,7-dimethoxychromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(O)=C1 PRIMEGXXBMBQFZ-UHFFFAOYSA-N 0.000 description 1
- BIRKWKNILZZAOF-UHFFFAOYSA-N 3-phenyl-2-(piperazin-1-ylmethyl)chromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(C=2C=CC=CC=2)=C1CN1CCNCC1 BIRKWKNILZZAOF-UHFFFAOYSA-N 0.000 description 1
- LJUHEEFEADORHV-UHFFFAOYSA-N 3-piperazin-1-ylbenzonitrile Chemical compound N#CC1=CC=CC(N2CCNCC2)=C1 LJUHEEFEADORHV-UHFFFAOYSA-N 0.000 description 1
- AYGYICRITMSJOC-UHFFFAOYSA-N 3-piperazin-1-ylphenol Chemical compound OC1=CC=CC(N2CCNCC2)=C1 AYGYICRITMSJOC-UHFFFAOYSA-N 0.000 description 1
- MKJHGVZTPBBKML-UHFFFAOYSA-N 4-(4-benzylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-one Chemical class C=12NC(=O)NC2=CC=CC=1N(CC1)CCN1CC1=CC=CC=C1 MKJHGVZTPBBKML-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ULNBYXZTXGEMJE-UHFFFAOYSA-N 4-piperazin-1-yl-1,3-dihydrobenzimidazol-2-one Chemical compound C=12NC(=O)NC2=CC=CC=1N1CCNCC1 ULNBYXZTXGEMJE-UHFFFAOYSA-N 0.000 description 1
- YZKSXUIOKWQABW-UHFFFAOYSA-N 4-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC=CC2=C1C=CN2 YZKSXUIOKWQABW-UHFFFAOYSA-N 0.000 description 1
- DANDEJPAZFBPAS-UHFFFAOYSA-N 5-amino-1h-quinolin-2-one Chemical compound OC1=CC=C2C(N)=CC=CC2=N1 DANDEJPAZFBPAS-UHFFFAOYSA-N 0.000 description 1
- NRZABPOFVNBWMI-UHFFFAOYSA-N 5-nitro-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C=CC=C2[N+](=O)[O-] NRZABPOFVNBWMI-UHFFFAOYSA-N 0.000 description 1
- XUHJGVVLASAEOK-UHFFFAOYSA-N 6,7-dimethoxy-3-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]chromen-4-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 XUHJGVVLASAEOK-UHFFFAOYSA-N 0.000 description 1
- OMJJWMGXOLTUDX-UHFFFAOYSA-N 6-bromo-1-(2,4,5-trimethoxyphenyl)hexan-1-one Chemical compound COC1=CC(OC)=C(C(=O)CCCCCBr)C=C1OC OMJJWMGXOLTUDX-UHFFFAOYSA-N 0.000 description 1
- UIKHCJNIMBXYAB-UHFFFAOYSA-N 6-bromo-1-(2-hydroxy-4-methoxyphenyl)hexan-1-one Chemical compound COC1=CC=C(C(=O)CCCCCBr)C(O)=C1 UIKHCJNIMBXYAB-UHFFFAOYSA-N 0.000 description 1
- VPEYDWMRYFKGRP-UHFFFAOYSA-N 6-bromo-1-(2-hydroxy-5-methoxyphenyl)hexan-1-one Chemical compound COC1=CC=C(O)C(C(=O)CCCCCBr)=C1 VPEYDWMRYFKGRP-UHFFFAOYSA-N 0.000 description 1
- FBGKIAUPSQHOSI-UHFFFAOYSA-N 6-bromo-1-(3-methoxycyclohex-2-en-1-yl)hexan-1-one Chemical compound COC1=CC(C(=O)CCCCCBr)CCC1 FBGKIAUPSQHOSI-UHFFFAOYSA-N 0.000 description 1
- VXSCBZMUCCMKMQ-UHFFFAOYSA-N 7-[4-[4-(1h-indol-4-yl)piperazin-1-yl]butyl]-[1,3]dioxolo[4,5-g]chromen-8-one Chemical compound C1=C2C(=O)C(CCCCN3CCN(CC3)C=3C=4C=CNC=4C=CC=3)=COC2=CC2=C1OCO2 VXSCBZMUCCMKMQ-UHFFFAOYSA-N 0.000 description 1
- IIIBEFZGXYHYCF-UHFFFAOYSA-N 7-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC2=C1OC(=O)N2 IIIBEFZGXYHYCF-UHFFFAOYSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- BJJMRBXZMKJLQK-UHFFFAOYSA-N 7-piperazin-1-yl-3h-1,3-benzoxazol-2-one Chemical compound C=12OC(=O)NC2=CC=CC=1N1CCNCC1 BJJMRBXZMKJLQK-UHFFFAOYSA-N 0.000 description 1
- 206010072413 Action tremor Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 1
- 206010012219 Deliria Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005618 Fries rearrangement reaction Methods 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- SSSFVOZQXFWWBD-UHFFFAOYSA-N Oc(c(C(CCCCCBr)=O)c1)cc2c1OCO2 Chemical compound Oc(c(C(CCCCCBr)=O)c1)cc2c1OCO2 SSSFVOZQXFWWBD-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 210000003818 area postrema Anatomy 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 150000008365 aromatic ketones Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- ZIEHOXTUNZBCDI-UHFFFAOYSA-N chromen-4-one 1-phenylpiperazine Chemical class C1=CC=C2C(=O)C=COC2=C1.C1CNCCN1C1=CC=CC=C1 ZIEHOXTUNZBCDI-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- HFPGRVHMFSJMOL-UHFFFAOYSA-N dibromomethane Chemical group Br[CH]Br HFPGRVHMFSJMOL-UHFFFAOYSA-N 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920005555 halobutyl Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- MOMDHKVDJYHNRF-UHFFFAOYSA-N hexan-1-one Chemical compound CCCCC[C]=O MOMDHKVDJYHNRF-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- RHDXTIJLLREGCE-UHFFFAOYSA-N n-[3-[4-[4-(6,7-dimethoxy-4-oxochromen-3-yl)butyl]piperazin-1-yl]phenyl]methanesulfonamide Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2OC=C1CCCCN(CC1)CCN1C1=CC=CC(NS(C)(=O)=O)=C1 RHDXTIJLLREGCE-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000436 pro-erectile effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
- 229950001037 quinpirole Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ROWMQJJMCWDJDT-UHFFFAOYSA-N tribromomethane Chemical group Br[C](Br)Br ROWMQJJMCWDJDT-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Definitions
- the invention relates to chromone derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their therapeutic applications as agonists, partial agonists or antagonists of the dopamine receptor D3 (DRD3) for the treatment of various neurological and psychiatric conditions.
- D3 dopamine receptor D3
- Schizophrenia is a term used to describe a group of pathologies of unknown origin that affects approximately 1 % of the general population. This pathology is characterised by a variety of symptoms, classified as positive symptoms (hallucinations, deliria, disorganised thought) and negative symptoms (social withdrawal and affective flattening), at an age commencing in adolescence or the beginning of adulthood, and can persist in chronic form with episodes of exacerbation for many years.
- neuroleptics also known by the name antipsychotics.
- the therapeutic effect of antipsychotics is generally acknowledged as resulting from the blockade of receptors of the neuromediator dopamine in the brain.
- D1 , D2, D3, D4 and D5 There are five known sub-types of dopamine receptors, called D1 , D2, D3, D4 and D5 (Sokoloff, P. er a/., Novel dopamine receptor subtypes as targets for antipsychotic drugs.
- Annals New-York Academy of Sciences 1995, 757, 278) and the conventional antipsychotics are D2 and D3 receptor antagonists.
- the selective modulation of DRD3 receptors can be achieved with molecules that bind selectively to DRD3 and that act as agonists, as antagonists or as partial agonists.
- the antipsychotic activity resulting from the modulation of DRD3 function can be predicted in animals by employing schizophrenic mouse models (Leriche L. et a/., Neuropharmacology 2003, 45, 174). It has moreover been demonstrated that selective blockade of DRD3, but not the concomitant blockade of DRD2 and DRD3, increases the extracellular levels of dopamine and acetylcholine, another neuromediator, in the prefrontal cortex (Lacroix L . et al., Neuropsychophamacol. 2003, 28, 839). Dopamine and acetylcholine in that region of the brain are essential for cognitive function. It is consequently thought that selective antagonists of DRD3 can improve cognition, which is altered in schizophrenia and also in neurodegenerative pathologies such as Alzheimer's disease.
- Antipsychotics in general and aripiprazole, quetiapine and olanzapine in particular, are used in the treatment of the acute manic phase of bipolar disorder.
- Antagonists or partial agonists of DRD3 are thus also considered as medicaments for the treatment of bipolar disorder.
- Depression is a common mood pathology that is characterised by feelings of intense sadness, pessimistic thoughts and self-depreciation, often accompanied by loss of energy, enthusiasm and libido.
- the incapacity to feel pleasure from normally pleasant experiences, also known by the name of anhedonia, is also regarded as a common symptom in depression .
- a significant role in pleasure and motivation has been attributed to the dopaminerg ic neurons in a reg ion of the bra in cal led the nucleus accumbens (Koob G.F. et al., Sem. Neurosci. 1992, 4, 139 ; Salamone J.D. et al., Behav. Brain Res. 1994, 61, 1 17).
- DRD3 is abnormally high in the brain of cocaine addicts (Staley J.K. et ai, J. Neurosci. 1996, 16, 6106). Partial agonists or antagonists of DRD3 are therefore thought to be effective medicaments for facilitating abstinence and reducing the risk of relapse.
- Parkinson's disease is a pathology characterised by tremor at rest, limb rigidity and akinesia (difficulty in initiating movements). The disease is caused by a degeneration of dopaminergic neurons.
- the treatment of Parkinson's disease is based on the substitution of dopamine through the administration of L- dihydroxyphenylamine (L-DOPA) or direct dopamine agonists. Long-term use of L- DOPA, however, is associated in a very sign ificant number of cases with the occurrence of abnormal movements called dyskinesias. It has been demonstrated in a non-human primate model of Parkinson's disease that the modulation of DRD3 with a highly selective partial agonist attenuates dyskinesias (Bezard E. et ai, Nat. Med.
- a mutation in the DRD3 gene is associated and co-segregated with essential tremor, a common and hereditary neurological disorder that is characterised by action tremor of all or part of the body in the absence of any other neurological pathology (Jeanneteau et al., Proc. Natl. Acad. Sci. USA 2006, 103, 10753).
- the mutation increases DRD3 function.
- the normalisation of DRD3 function by using partial agonists or antagonists of DRD3 might therefore be an effective treatment for essential tremor.
- Dopamine controls erectile function and dopaminergic agents have been proposed as a treatment for erectile dysfunction (Guiliano F., Ramplin O. Physiol Behav.2004, 83, 189-201). More specifically, the pro-erectile effects of dopaminergic agonists are mediated by the D3 receptor in rodents (Collins G.T. et al., J. Pharmacol. Exp. Ther., 2009, 329, 210-217) and a selective D3 receptor antagonist delays ejaculation during coitus in the rat (Clement P. et al., J. Sex. Med., 2009, 6, 980-988,). Agonists, partial agonists and antagonists of DRD3 such as those described in the present invention may thus be a treatment for various dysfunctions of erectile function.
- WO2006077487 and the patent specification EP1841752 describe heteroaryl phenylpiperazine butyl carboxamides as DRD3 ligands.
- Patent application WO2008009741 mentions chromene and thiochromene carboxamides demonstrating an affinity for the D3 dopaminergic receptor for use as antipsychotics.
- Patent application WO2006072608 mentions arylpiperazines having dopaminergic and serotonergic receptor modulating properties for use in neuropsychiatric disorders such as schizophrenia.
- the publication J. Med. Chem.2009, 52, 151 also mentions those same derivatives. All of the products described in the above-cited patent specifications have a carboxamide chain in their structure.
- the products of the present invention are distinguished from the described compounds by the fact that th ey d o n ot h ave a ca rboxa m id e ch a i n b u t, u n expected ly , a re poten t D 3 dopaminergic receptor ligands.
- D3 dopamine receptor As used above, the term "D3 dopamine receptor”, “D3 receptor” or “DRD3” denotes a dopam ine receptor sub-type chiefly expressed in the l imbic system (Sokoloff P et ai, Nature, 1990, 347, 146-151 ). DRD3 is described in international patent application WO 91 /15513.
- D3 receptor partial agonist denotes a compound that forms a complex with DRD3 and acts as a combined agonist-antagonist, that is to say it induces a physiolog ical response of an intensity lower than that of the natural mediator, dopamine.
- a DRD3 partial agonist produces an active response the maximum intensity of which is lower than that produced by dopamine or by a full agonist, for example quinpirole (trans(-)-4aR- 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1 H(or 2 H)pyrazolo[3,4g]qu inol ine) .
- a DRD3 partial agonist may also partially prevent the response produced by dopamine or its full agonists.
- a DRD3 partial agonist produces dopaminergic responses, especially when the levels of dopamine are reduced, as is the case in rats having lesions caused by 6-hydroxydopamine or in monkeys intoxicated with 1 methyl-4- phenyl-1 ,2,3,6-tetrahydropyridine (MPTP).
- MPTP 1 methyl-4- phenyl-1 ,2,3,6-tetrahydropyridine
- a DRD3 partial agonist may act as an a ntagon ist, especially when the DRD3 is subject to sustained stimulation by dopamine.
- a DRD3 antagonist denotes a molecule that forms a complex with DRD3 and is capable of preventing a response triggered by dopamine or an agonist thereof in a cell expressing DRD3.
- salts denotes inorganic acid and base addition salts of the compounds of the present invention.
- the salts are pharmaceutically acceptable, that is to say, they are non-toxic for the patient to whom they are administered.
- pharmaceutically acceptable refers to molecular entities and compositions that do not produce any adverse allergic effect or other undesirable reaction when administered to an animal or human.
- the expression "pharmaceutically acceptable excipient” includes any diluent, adjuvant or excipient, such as preservative, filler disintegrator, wetting agent, emulsifier, dispersant, antibacterial or antifungal agent, or also agents that would allow intestinal and digestive absorption and resorption to be delayed.
- diluent such as preservative, filler disintegrator, wetting agent, emulsifier, dispersant, antibacterial or antifungal agent, or also agents that would allow intestinal and digestive absorption and resorption to be delayed.
- preservative such as preservative, filler disintegrator, wetting agent, emulsifier, dispersant, antibacterial or antifungal agent, or also agents that would allow intestinal and digestive absorption and resorption to be delayed.
- wetting agent such as a emulsifier, dispersant, antibacterial or antifungal agent, or also agents that would allow intestinal and digestive absorption and resorption to be delayed.
- emulsifier such as
- treatment means preventing or inhibiting the appearance or progression of the condition to which the term is applied, or of one or more symptoms of that condition.
- “Therapeutically active amount” means an amount of a chromone derivative that is effective in obtaining the desired therapeutic effect according to the invention.
- the term “patient” refers to a human or non-human mammal affected or very susceptible to being affected by a pathology.
- the patient is a human.
- a C1 -4alkyl group is understood as a linear or branched hydrocarbon chain containing from 1 to 4 carbon atoms, for example a methyl group, an ethyl group, a propyl group or a butyl group.
- a Ci -4 alkoxy group is understood as a linear or branched hydrocarbon chain containing from 1 to 4 carbon atoms and an oxygen atom, for example a methoxy group, an ethoxy group, a propoxy group or a butoxy group.
- a Ci -4 thioalkoxy group is understood as a linear or branched hydrocarbon chain containing from 1 to 4 carbon atoms, an oxygen atom and a sulfur atom, for example a thiomethoxy group, a thioethoxy group, a thiopropoxy group or a thiobutoxy group.
- Ci -4 dialkylamino group is understood as an amine disubstituted by linear or branched Ci -4 alkyl groups, for example a dimethylamino group, a diethylamino group, a dipropylamino group or a dibutylamino group.
- halogen is understood as fluorine, chlorine or bromine.
- a Ci -4 haloalkyl group is understood as a Ci -4 alkyl group monosubstituted, disubstituted or trisubstituted by a halogen, for example a CF 3 group, a CHF 2 group, a CH 2 F group, a CCI3 group, a CHCI2 group, a CH 2 CI group, a CBr 3 group, a CHBr 2 group or a CH 2 Br group.
- a halogen for example a CF 3 group, a CHF 2 group, a CH 2 F group, a CCI3 group, a CHCI2 group, a CH 2 CI group, a CBr 3 group, a CHBr 2 group or a CH 2 Br group.
- a Ci -4 dialkylaminoalkyl group is understood as a Ci -4 dialkylamino group as defined hereinbefore bonded to a Ci -4 alkyl group by a carbon atom, for example a dimethylaminomethyl group, a dimethylaminoethyl group, a diethylaminomethyl group or a diethylaminoethyl group.
- a Ci -4 alkoxyalkyl group is understood as a Ci- 4 alkyl group as defined hereinbefore bonded to a Ci -4 alkoxy group by a carbon atom, for example a methoxymethyl group, an ethoxymethyl group, a methoxyethyl group or an ethoxyethyl group.
- a Ci -4 hydroxyalkyl group is understood as an alkyl group as defined hereinbefore in which a hydrogen atom is substituted by a hydroxyl group, for example a CH 2 OH group, a C 2 H 4 OH group, a C 3 H 6 OH group or a C 4 H 8 OH group.
- a Ci -4 alkylcarbonyl group is understood as an alkyl group as defined hereinbefore bonded to a carbonyl group by the carbon atom, for example a COCH 3 group, a COC 2 H5 group, a COC3H7 group or a COC 4 H 9 group.
- a Ci -4 alkoxycarbonyl group is understood as an alkoxy group as defined hereinbefore bonded to a carbonyl group by the carbon atom, for example a COOCH 3 group, a COOC 2 H5 group, a COOC3H7 group or a COOC 4 H 9 group.
- Ci -4 phenylalkyl group is understood as a phenyl g rou p bonded by a carbon atom to an al kyl grou p as defi ned hereinbefore.
- the invention relates to chromone derivatives, to processes for their preparation, and to their use as a medicament, as DRD3 receptor ligands, for the treatment of neurological or psychiatric diseases, conditions or disorders.
- Those compounds correspond to the general formula 1 .
- R2 represents a hydrogen atom or a Ci -4 alkyl group.
- a and B represent, independently, either a nitrogen atom or a carbon atom.
- R3 constitutes a ring fused with the benzene ring carrying it, selected from the group composed of a naphthalene, an indole, a benzimidazole, a carbostyril, a benzoxazolone and a benzimidazolone.
- R4 represents a Ci -4 alkyl group or a Ci -4 dialkylamino group or a Ci -4 alkoxyalkyl group or a Ci -4 dialkylaminoalkyl group or a phenyl or phenyl-Ci -4 alkyl group,
- R5 represents a hydrogen atom or a Ci -4 alkylcarbonyl group or a Ci -4 alkoxy- carbonyl group
- R2 represents a hydrogen atom
- compou nds of the general formula (I) are those wherein R3 represents a hydrogen atom when A and/or B represent a nitrogen atom.
- compounds of the general formula (I) are those wherein :
- compounds of the general formula (I) are those wherein :
- compounds of the general formula (I) are those wherein :
- A represents a carbon atom and B represents a nitrogen atom or a carbon atom
- R3 represents one or two identical or different substituent(s) selected from the group composed of: a hydrogen atom, a CN group, a chlorine atom, a fluorine atom, an OH group, an NO 2 group, an NHSO 2 R4 group, an NHR5 group, a CF3 group, a methoxy group,
- R3 constitutes a ring fused with the benzene ring carrying it sel ected from the g rou p com posed of: benzi m idazol e , benzoxazolone, indole, benzimidazolone and carbostyril.
- R4 represents a methyl group, or an ethyl group, or a dimethylaminoethyl group or an ethoxymethyl group.
- R5 represents a hydrogen atom, a COCH3 group or a COOCH3 group
- the invention relates also to pharmaceutically acceptable salts thereof, as well as to pharmaceutical compositions containing them, and to their use as medicaments intended for the treatment of disorders of the central nervous system.
- the present invention relates also to a process for the preparation of those compounds.
- That reaction uses an omega halogenated hexanoic acid hal ide, such as 6-bromohexanoyl chloride. Condensation takes place with or without solvent in the presence of a Lewis acid, such as AICI3, according to a method analogous to that described in Chem. Ber. 1939, 72, 1414, or J. Org. Chem. 1955, 20, 38 with chloro or bromoacetyl chloride or bromide.
- the reaction uses bromohexanoyl chloride, wh ich is condensed in the ortho position of the phenol function to form derivative 3.
- a chlorinated solvent such as methylene chloride
- dichloroethane or 1 ,1 -2,2- tetrach loroeth an e for exam pl e , m ay be u sed .
- the ph enol s u sed with the corresponding substituents are either commercially available, or known from the literature and prepared by demethylation in the presence of agents conventionally employed to demethylate aromatic methoxy compounds, such as HBr and Lewis acids (AICI3, BBr 3 ).
- agents conventionally employed to demethylate aromatic methoxy compounds such as HBr and Lewis acids (AICI3, BBr 3 ).
- the Friedel Crafts reaction ca n a l so be ca rri ed out on a methoxylated aromatic ring rich in electrons.
- the demethylation step yielding the intermediate 3 can take place after the acylation step.
- That cyclisation to form a chromone can also be carried out in DMF in the presence of PCI 5 and etherate of BF 3 , as well as with ethyl formate in the presence of sodium according to Bull. Soc. Chim. Fr. 1944, 5, 302.
- halobutyl chromone derivative 4 is then brought together with substituted arylpiperazines or heteroarylpiperazines of formula 5 in standard manner in the presence of a base such as K2CO3 or caesium carbonate in acetonitrile or methyl ethyl ketone to yield derivatives of formula 1 . That procedure is used with piperazines of formula 5 wherein A, B and R3 are as defined hereinabove.
- a variant of the process can be used and comprises introducing the piperazine moiety prior to the formation of the chromone ring: thus, the condensation of the piperazine of formula 5 with the halogenated phenol of formula 3 under the same conventional alkylation conditions in basic medium (K2CO3 / CH 3 CN or methyl ethyl ketone) to yield compounds of formula 6.
- the aniline group can thus be acylated in the presence of pyridine or another base with acetyl chloride, yielding the acetamide derivative, with methyl chloroformate, yielding the methyl carbamate, or with methanesulfonyl chloride, yielding the methylsulfonamide.
- the reaction of the chloroethylsulfonyl chloride can be carried out in the same manner, and then the vinyl intermediate obtained can be brought together with dimethylamine or with sodium methoxide to yield, respectively, a dimethylaminoethylsulfonamide or methoxyethylsulfonamide substituent.
- Heterocyclic piperazines can be prepared by reaction of the corresponding anilines with nitrogen mustards (bischloroethylamines). Those nitrogen mustards can be N- substituted by a benzyl protecting group, which is removable by simple hydrogenolysis with Pd/C under hydrogen when the condensation with piperazine has been effected (Fr2504532 ; Fr2524884 ; Bioorg. Med. Chem. Lett. 1998, 8, 2675 ; Bioorg. Med. Chem. Let.2001, 11, 2345, J. Med. Chem.2002, 45, 4128 ; J. Med. Chem.2004, 47, 871 ; Synth. Commun.2006, 36, 1983 ; Synthesis 1977, 33 ; Tet. Let.1970, 5265 ; Chem. Pharm. Bull. 1981 , 29, 651 or 1979, 27, 2627 ; Tet. 2000, 56, 3245).
- nitrogen mustards can be N- substituted by a benzyl protecting group, which is removable by simple hydrogen
- the invention thus relates also to the following preparation processes:
- radicals R1 , R3, A and B have the meanings given hereinbefore, under alkylation conditions in the presence of a base such as K2CO3, CS2CO3 or NEt 3 , in a solvent such as acetonitrile or methyl ethyl ketone.
- the invention relates also to a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound of the general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
- the compounds of the invention are su itable in various therapeutic applications and do not interfere with dopaminergic transmissions of the extra-pyramidal, antehypophysial or vegetative systems (for example the area postrema).
- the compounds of the invention can thus be used for the preparation of pharmaceutical compositions and medicaments for the treatment of neurological or psychiatric disease, conditions or disorders involving the DRD3 receptor, such as psychotic states.
- the compounds of the invention are able to imitate the action of antidepressant med icaments.
- the compounds can thus be employed for the preparation of pharmaceutical compositions and medicaments for the treatment of depression.
- compositions or medicaments based on the compounds described in the present invention may usefully be administered in states associated with abstinence and/or to facilitate the detoxification of individuals dependent on cocaine, heroin, alcohol, tobacco, and other addictive substances.
- the compounds according to the invention may also be employed as a supplementary treatment to the treatment of Parkinson's disease with L-DOPA.
- the com pou nds accord i ng to the invention may also be employed for the treatment of essential tremor.
- l i ke partial agon ists and antagonists of the DRD3 receptor may also be employed for the treatment of essential tremor.
- compounds of formula 1_, bases or salts can be used for the treatment of neurological or psychiatric conditions, especially conditions that can be treated by DRD3 receptor agonists, partial agonists or antagonists.
- the invention relates also to a method of treating neurological or psychiatric conditions, diseases or disorders that comprises administering a compound of formula in a therapeutically effective amount to a patient requiring treatment.
- the invention relates in addition to compounds of formula 1. for their use as medicaments.
- the invention relates also to compounds of formula I for the manufacture of a medicament for the treatment of a neurological or psychiatric disease or disorder or erectile dysfunction or dependence on drugs or on addictive substances.
- the invention relates to compounds of the general formula (I) for the manufacture of a medicament for the treatment of Parkinson's disease, psychosis, schizophrenia, dyskinesias associated with Parkinson's disease, cogn itive deficiency optionally associated with age or with Alzheimer's disease, mood disorder, essential tremor, anxiety, depression , bipolar d isorder, sexual impotence, premature ejaculation, alcoholism and nicotine addiction.
- Compounds of formula 1_ according to the invention can be administered by the oral, systemic, parenteral, nasal or rectal route.
- the compound can especially be adm in istered by the oral route in an appropriate formulation .
- the dosages of the compounds of formula 1_ in the compositions of the invention can be adjusted to obtain an amount of active substance that is effective in obtain ing the desired therapeutic response for a composition peculiar to the method of administration.
- the dosage level chosen depends therefore on the desired therapeutic effect, the administration route, the desired duration of treatment and other factors.
- Compounds of formula 1 were evaluated in vitro as DRD3 ligands and modulators of the activity of that receptor in accordance with the invention in cells expressing human recombinant DRD3 receptor.
- the inhibition constants (K,) were measured by inhibition of the binding of [ 3 H]spiperone as described by Cussac et al., in Naunyn-Schmiedeberg's Arch. Pharmacol . 2000, 361, 569. Th e i nventors demonstrated that the compounds of formula 1 behave as potent ligands, with K, values from 0.1 to 30 nanomole. litre "1 . Those same compounds exhibit a noticeable affinity for the D2 receptor of dopamine that is from 10 to 200 times weaker.
- Compounds of formula 1_ were eval uated for their agon ist, partial agon ist, or antagonist activity by using the MAP-kinase activity test on human recombinant receptors described in Cussac D. et al., Mol. Pharmacol. 1999, 56, 1025-1030.
- the intrinsic activities of the compounds of formula l are between 0 (antagonist) and 0.80 (agonist).
- the total da ily dose of the compounds for use in accordance with th is invention may be in amounts of, for example, from 0.001 to approximately 100 mg/kg body weight daily.
- the specific dose level for any particular patient will depend on a variety of factors, incl ud ing body weight, general health , sex, d iet, du ration and route of admin istration , levels of intestinal absorption and resorption and of excretion , combination with other medicaments and the severity of the particular condition being treated.
- Step 1 6-bromo-1 -(2,4,5-trimethoxyphenyl)-hexan-1 -one 6 ml (40 mmol) of 1 ,2,4-trimethoxybenzene are introduced into 80 ml of dry CH2CI2 and the mixture is cooled to -10°C with stirring. 6-Bromohexanoyl chloride (6.2 ml, 40 mmol) dissolved in 20 ml of CH2CI2 is then added dropwise. AICI3 (5.6 g, 42 mmol) is progressively introduced in small portions into the reaction mixture. The reaction is maintained with stirring for 8h with a return to ambient temperature. The reaction mixture is then poured onto ice (200 ml) and acidified to pH 1 using HCI.
- Step 2 6-Bromo-1 -(2-hydroxy-4,5-dimethoxyphenyl)-hexan-1 -one.
- Step 3 3-(4-Bromobutyl)-6,7-dimethoxychromen-4-one 1 method : A solution A is prepared from 500 mg of the compound of the above Step, 6-bromo-1 -(2-hydroxy-4,5-dimethoxyphenyl)-hexan-1 -one (1 .5 mmol), dissolved in 0.60 ml (4.5 mmol) of Et 2 O-BF 3 , and the solution is cooled to 10°C. 2.3 ml of DMF are then added. There is prepared, in addition, a solution B of 4 ml of DMF and there is added thereto in small portions at 10°C 470 mg (2.25 mmol) of PCI 5 .
- Solution B is heated at 55°C for 20 min, and is then introduced dropwise into solution A, referred to at the beginning, with a return to ambient temperature.
- the mixture turns orangey yellow and precipitates.
- 50 ml of 0.1 N HCI are introduced and the mixture is extracted with AcOEt, the organic phases are washed with saturated NaCI solution, separated, dried over MgSO 4 , filtered and evaporated .
- the residue is subjected to flash chromatography over S1O2 with a gradient of pure heptane to heptane-AcOEt 70-30. The purified fractions crystallise after evaporation.
- Step 4 6,7-Dimethoxy-3- ⁇ 4-[4-(2-methoxyphenyl)-piperazin-1 -yl]-butyl ⁇ -chromen-4- one.
- the brominated derivative obtained in the above Step 3 (1 50 mg , 0.44 mmol) is suspended i n 1 0 m l of m ethyl ethyl keton e , a nd 1 20 mg (0.62 m mol ) of 2- methoxyphenylpiperazine and 121 mg (0.87 mmol) of K2CO3, as well as 1 0 mg of tetrabutylammonium bromide, are added.
- the mixture is refluxed for 20 h and then concentrated.
- the residue is taken up in water and extracted with ethyl acetate.
- the organic phases are separated, dried over MgSO4, filtered and evaporated to yield a colourless oil.
- Example 3 3- ⁇ 4-[4-(2,3-Dichlorophenyl)-piperazin-1-yl]-butyl ⁇ -6,7- dimethoxychromen-4-one.
- Example 4 3- ⁇ 4-[4-(3-Hydroxyphenyl)-piperazin-1 -yl]-butyl ⁇ -6,7- dimethoxychronnen-4-one.
- Example 5 6,7-Dimethoxy-3-[4-(4-pyrimidin-2-yl-piperazin-1 -yl)-butyl]- chromen-4-one.
- Example 6 6,7-Dimethoxy-3-[4-(4-pyridin-2-yl-piperazin-1 -yl)-butyl]- chromen-4-one.
- Example 7 3- ⁇ 4-[4-(2,3-Difluorophenyl)-piperazin-1 -yl]-butyl ⁇ -6,7- dimethoxychronnen-4-one,
- Example 8 3- ⁇ 4-[4-(1 H-Benzimidazol-4-yl-)piperazin-1 -yl]-butyl ⁇ -6,7- dimethoxychromen-4-one.
- Example 9 3- ⁇ 4-[4-(1 H-lndol-4-yl)-piperazin-1 -yl]-butyl ⁇ -6,7- dimethoxychromen-4-one.
- 4-indolyl-piperazine described in J. Med. Chem. 2002, 45, 4128 3- ⁇ 4-[4-(1 H-indol-4-yl-)piperazin-1 -yl]-butyl ⁇ -6,7- dimethoxychromen-4-one is obtained in a yield of 69%.
- Step 2 5-Piperazin-1 -yl-1 H-quinolin-2-one.
- Step 3 5- ⁇ 4-[4-(6,7-Dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin-1 -yl ⁇ -1 H- quinolin-2-one.
- Example 11 6,7-Dimethoxy-3- ⁇ 4-[4-(3-nitrophenyl)-piperazin-1 -yl]-butyl ⁇ - chromen-4-one.
- Example 12 3- ⁇ 4-[4-(3-Aminophenyl)-piperazin-1 -yl-]-butyl ⁇ -6,7- dimethoxychromen-4-one.
- the nitro compound of the above Example 1 1 (910 mg, 1 .95 mmol) is hydrogenated in a mixture of 50 ml of CH 2 CI 2 and 50 ml of EtOH with 91 mg of 10% Pd/C under a hydrogen atmosphere for 24h with vigorous stirring. After removal of the catalyst by filtration and after evaporation, 720 mg of pink crystals are isolated.
- Example 13 N-(3- ⁇ 4-[4-(6,7-Dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]- piperazin-1 -yl ⁇ -phenyl)-methanesulfonamide.
- Example 14 N-(3- ⁇ 4-[4-(6,7-Dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]- piperazin-1 -yl ⁇ -phenyl)-acetamide.
- Example 15 Methyl (3- ⁇ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]- piperazin-1 -yl ⁇ -phenyl)-carbamate.
- Example 12 In a similar manner to Example 1 3, but using methyl chloroformate and 3- ⁇ 4-[4-(3- aminophenyl)-piperazin-1 -yl-]-butyl ⁇ -6,7-dimethoxychromen-4-o n e o b t a i n e d i n
- Example 12 methyl (3- ⁇ 4-[4-(6,7-dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]-piperazin- 1 -yl ⁇ -phenyl)-carbamate is obtained.
- Example 16 7- ⁇ 4-[4-(2,3-Dichlorophenyl)-piperazin-1 -yl]-butyl ⁇ - [1 ,3]dioxolo[4,5-g]chromen-8-one.
- Step 1 Preparation of 6-bromo-1 -(6-hydroxybenzo[1 ,3]dioxo-5-yl)-hexane-1 -
- a solution of 1 g (7.2 mmol) of sesamol in 20 ml of CH2CI2 is cooled to -10°C with stirring .
- 1 .1 ml (7.2 mmol) of 6-bromohexanoyl chloride is added, and then 1 g (7.6 mnnol) of AICI3 in small portions.
- the temperature is allowed to rise to ambient temperature and stirring is maintained for 18 h.
- Hydrolysis is carried out by adding ice and acidification is carried out with concentrated HCI (2 ml).
- 6-Bromo-1 -(2-hydroxy-5-methoxyphenyl)-hexan-1 -one is prepared in identical manner.
- Step 2 Preparation of 6-[4-(2,3-dichlorophenyl)-piperazin-1 -yl]-1 -(6- hydroxybenzo[1 ,3]dioxol-5-yl)-hexan-1 -one.
- Step 3 7- ⁇ 4-[4-(2,3-Dichlorophenyl)-piperazin-1 -yl]-butyl ⁇ -[1 ,3]dioxolo[4,5-g]chromen- 8-one
- Example 18 7- ⁇ 4-[4-(3-Nitrophenyl)-piperazin-1-yl]-butyl ⁇ -[1 ,3]dioxolo[4,5- g]chromen-8-one.
- Example 19 7- ⁇ 4-[4-(3-Aminophenyl)-piperazin-1-yl]-butyl ⁇ -[1 ,3]dioxolo[4,5- g]chromen-8-one.
- Example 20 N-(3- ⁇ 4-[4-(8-Oxo-8H-[1 ,3]dioxolo[4,5-g]chromen-7-yl)-butyl]- piperazin-1-yl ⁇ -phenyl-acetamide.
- Example 21 N-(3- ⁇ 4-[4-(8-Oxo-8H-[1 ,3]dioxolo[4,5-g]chromen-7-yl)-butyl]- piperazin-1 -yl ⁇ -phenyl)-methanesulfonamide.
- Example 19 In an analogous manner to Example 13, but using 7- ⁇ 4-[4-(3-aminophenyl)-piperazin- 1 -yl]-butyl ⁇ -[1 ,3]dioxolo[4,5-g]chromen-8-one obtained in Example 19 instead of 3- ⁇ 4- [4-(3-aminophenyl)-piperazin-1 -yl-]-butyl ⁇ -6,7-dimethoxychromen-4-o n e , N-(3- ⁇ 4-[4- (8-oxo-8H-[1 ,3]dioxolo[4,5-g]chromen-7-yl)-butyl]-piperazin-1 -yl ⁇ -phenyl)- methanesulfonamide is obtained.
- Example 22 N-(3- ⁇ 4-[4-(8-Oxo-8H-[1 ,3]dioxolo[4,5-g]chromen-7-yl)- butyl]-piperazin-1 -yl ⁇ -phenyl)-ethanesulfonamide.
- Example 23 2-dimethylaminoethanesulfonic acid (3- ⁇ 4-[4-(8-oxo-8H- [1 ,3]dioxolo[4,5-g]chromen-7-yl)-butyl]-piperazin-1 -yl ⁇ -phenyl)-amide.
- Step 1 In a similar manner to Example 21, 7- ⁇ 4-[4-(3-aminophenyl)-piperazin-1-yl]- butyl ⁇ -[1,3]dioxolo[4,5-g]chromen-8-one is condensed with 2-chloroethylsulfonyl chloride. (3- ⁇ 4-[4-(8-oxo-8H-[1 ,3]dioxolo[4,5-g]chromen-7-yl)-butyl]-piperazin-1 -yl ⁇ - phenyl)-ethenesulfonamide is obtained.
- Step 2 The compound of the above Step 1 (100 mg, 0.2 mmol) is introduced into a sealed tube with 2 ml of 2M dimethylamine solution in MeOH at ambient temperature for 3 h. The batch is evaporated to dryness, and the residue is triturated with isopropanol HCI, the hydrochloride is introduced into iPr 2 O and filtered.
- Example 25 7- ⁇ 4-[4-(1 H-lndol-4-yl)-piperazin-1-yl]-butyl ⁇ -[1 ,3]dioxolo[4,5- g]chromen-8-one.
- Example 26 3- ⁇ 4-[4-(3-Thfluoromethylphenyl)-piperazin-1-yl]-butyl ⁇ -6,7- dimethoxychronnen-4-one.
- Example 27 6-Methoxy-3-[4-(4-phenyl-piperazin-1-yl)-butyl]-chromen-4- one.
- Example 28 6-Methoxy-3- ⁇ 4-[4-(2-methoxyphenyl)-piperazin-1 -yl]-butyl ⁇ - chromen-4-one.
- 6-methoxy-3- ⁇ 4-[4-(2-methoxyphenyl)-piperazin-1 -yl]-butyl ⁇ -chromen-4-one is prepared in the form of white hydrochloride crystals.
- M.p.°C 1 91
- C 2 5H 3 iCIN 2 O 4 458.97, calc. C%65.42, H%6.81 , N%6.10, Cl%7.72, found C%66.28, H%6.88, N%6.08, Cl%7.64%.
- Example 29 6-Methoxy-3- ⁇ 4-[4-(3-trifluoromethylphenyl)-piperazin-1 -yl]- butyl ⁇ -chromen-4-one.
- Example 30 7- ⁇ 4-[4-(2,3-Dichlorophenyl)piperazin-1 -yl-]-butyl ⁇ -6-methyl- [1 ,3]dioxolo[4,5-g]chromen-8-one.
- Example 32 7- ⁇ 4-[4-(6,7-Dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]- piperazin-1 -yl ⁇ -3H-benzoxaz -2-one.
- Example 33 4- ⁇ 4-[4-(6,7-Dimethoxy-4-oxo-4H-chromen-3-yl)-butyl]- piperazin-1 -yl ⁇ -1 ,3-dihydrobenzimidazol-2-one.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK10754594.9T DK2470520T3 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, processes for their preparation and their therapeutic uses |
US13/393,542 US8546402B2 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
PL10754594T PL2470520T3 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
NZ597930A NZ597930A (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
MX2012002543A MX2012002543A (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications. |
BR112012003741-2A BR112012003741B1 (en) | 2009-09-01 | 2010-08-31 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS |
CN201080038431.7A CN102482251B (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
JP2012527432A JP5786229B2 (en) | 2009-09-01 | 2010-08-31 | Chromon derivatives, their preparation and therapeutic applications |
UAA201202432A UA109260C2 (en) | 2009-09-01 | 2010-08-31 | CHROMON DERIVATIVES, METHODS OF THEIR PREPARATION AND THERAPEUTIC APPLICATIONS |
RU2012106743/04A RU2545214C2 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, method for preparing them and therapeutic uses thereof |
EP10754594.9A EP2470520B1 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
ES10754594T ES2428751T3 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a procedure for their preparation and therapeutic applications thereof |
SG2012006870A SG178198A1 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
AU2010290871A AU2010290871B2 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
SI201030323T SI2470520T1 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
CA2771061A CA2771061C (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
KR1020127005385A KR101663635B1 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
IL217729A IL217729A (en) | 2009-09-01 | 2012-01-25 | 3-[(piperazin-1-yl)butyl]-4h-chromen-4-one derivatives, processes for their preparation and pharmaceutical compositions comprising them |
TNP2012000049A TN2012000049A1 (en) | 2009-09-01 | 2012-01-31 | Chromone derivatives a process for their preparation and their therapeutic application |
ZA2012/00770A ZA201200770B (en) | 2009-09-01 | 2012-01-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
MA34616A MA35674B1 (en) | 2009-09-01 | 2012-02-09 | Chromone derivatives, process for their preparation and therapeutic applications |
HK12111043.0A HK1170724A1 (en) | 2009-09-01 | 2012-11-02 | Chromone derivatives, a process for their preparation and their therapeutic applications |
HRP20130832AT HRP20130832T1 (en) | 2009-09-01 | 2013-09-06 | Chromone derivatives, a process for their preparation and their therapeutic applications |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0955944 | 2009-09-01 | ||
FR0955944A FR2949465B1 (en) | 2009-09-01 | 2009-09-01 | CHROMIUM DERIVATIVES, PROCESS FOR PREPARING THEM AND THERAPEUTIC APPLICATIONS THEREOF |
US33699210P | 2010-01-29 | 2010-01-29 | |
US61/336,992 | 2010-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011027289A1 true WO2011027289A1 (en) | 2011-03-10 |
Family
ID=41403421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/053895 WO2011027289A1 (en) | 2009-09-01 | 2010-08-31 | Chromone derivatives, a process for their preparation and their therapeutic applications |
Country Status (32)
Country | Link |
---|---|
US (1) | US8546402B2 (en) |
EP (1) | EP2470520B1 (en) |
JP (1) | JP5786229B2 (en) |
KR (1) | KR101663635B1 (en) |
CN (1) | CN102482251B (en) |
AR (1) | AR078114A1 (en) |
AU (1) | AU2010290871B2 (en) |
BR (1) | BR112012003741B1 (en) |
CA (1) | CA2771061C (en) |
CL (1) | CL2012000516A1 (en) |
CO (1) | CO6491096A2 (en) |
DK (1) | DK2470520T3 (en) |
ES (1) | ES2428751T3 (en) |
FR (1) | FR2949465B1 (en) |
GE (1) | GEP20146080B (en) |
HK (1) | HK1170724A1 (en) |
HR (1) | HRP20130832T1 (en) |
IL (1) | IL217729A (en) |
MA (1) | MA35674B1 (en) |
MX (1) | MX2012002543A (en) |
MY (1) | MY162345A (en) |
NZ (1) | NZ597930A (en) |
PL (1) | PL2470520T3 (en) |
PT (1) | PT2470520E (en) |
RU (1) | RU2545214C2 (en) |
SG (1) | SG178198A1 (en) |
SI (1) | SI2470520T1 (en) |
TN (1) | TN2012000049A1 (en) |
TW (1) | TWI510483B (en) |
UA (1) | UA109260C2 (en) |
WO (1) | WO2011027289A1 (en) |
ZA (1) | ZA201200770B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957088B2 (en) | 2008-08-05 | 2015-02-17 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
US8969568B2 (en) | 2010-01-29 | 2015-03-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted naphthyridines and their use as medicaments |
US9199937B2 (en) | 2011-07-26 | 2015-12-01 | Boehringer Ingelheim International Gmbh | Substituted quinolines and their use as medicaments |
US10028948B2 (en) | 2013-12-13 | 2018-07-24 | Pierre Fabre Medicament | Chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder |
WO2019086661A1 (en) | 2017-11-03 | 2019-05-09 | Pierre Fabre Medicament | Treatment of schizophrenia |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS56654B8 (en) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviral compounds |
DE202012013074U1 (en) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Compositions for the treatment of HCV |
CN104144682A (en) | 2013-01-31 | 2014-11-12 | 吉利德法莫赛特有限责任公司 | Combination formulation of two antiviral compounds |
ES2900570T3 (en) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN112220782B (en) * | 2020-11-11 | 2021-08-20 | 中国人民解放军军事科学院军事医学研究院 | Application of 1,2, 4-trimethoxy benzene in preventing and treating posttraumatic stress disorder |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089497A (en) * | 1990-09-20 | 1992-02-18 | Warner-Lambert Company | Substituted piperazines as central nervous system agents |
US20050197343A1 (en) * | 2002-07-04 | 2005-09-08 | Peter Gmeiner | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
EP1683790A1 (en) * | 2005-01-24 | 2006-07-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
WO2008009741A1 (en) * | 2006-07-21 | 2008-01-24 | Pierre Fabre Medicament | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4233963A1 (en) * | 1992-10-08 | 1994-04-14 | Schwabe Willmar Gmbh & Co | New benzopyranone, process for its preparation and use |
CN101115743B (en) * | 2005-02-18 | 2011-04-13 | 阿皮德公开股份有限公司 | Novel processes for the preparation of a 2H-chromene |
-
2009
- 2009-09-01 FR FR0955944A patent/FR2949465B1/en not_active Expired - Fee Related
-
2010
- 2010-08-10 TW TW099126581A patent/TWI510483B/en not_active IP Right Cessation
- 2010-08-30 AR ARP100103170A patent/AR078114A1/en active IP Right Grant
- 2010-08-31 NZ NZ597930A patent/NZ597930A/en not_active IP Right Cessation
- 2010-08-31 CN CN201080038431.7A patent/CN102482251B/en not_active Expired - Fee Related
- 2010-08-31 SI SI201030323T patent/SI2470520T1/en unknown
- 2010-08-31 AU AU2010290871A patent/AU2010290871B2/en not_active Ceased
- 2010-08-31 SG SG2012006870A patent/SG178198A1/en unknown
- 2010-08-31 BR BR112012003741-2A patent/BR112012003741B1/en not_active IP Right Cessation
- 2010-08-31 RU RU2012106743/04A patent/RU2545214C2/en active
- 2010-08-31 JP JP2012527432A patent/JP5786229B2/en active Active
- 2010-08-31 MY MYPI2012000354A patent/MY162345A/en unknown
- 2010-08-31 ES ES10754594T patent/ES2428751T3/en active Active
- 2010-08-31 PT PT107545949T patent/PT2470520E/en unknown
- 2010-08-31 US US13/393,542 patent/US8546402B2/en active Active
- 2010-08-31 DK DK10754594.9T patent/DK2470520T3/en active
- 2010-08-31 EP EP10754594.9A patent/EP2470520B1/en active Active
- 2010-08-31 MX MX2012002543A patent/MX2012002543A/en active IP Right Grant
- 2010-08-31 WO PCT/IB2010/053895 patent/WO2011027289A1/en active Application Filing
- 2010-08-31 KR KR1020127005385A patent/KR101663635B1/en active IP Right Grant
- 2010-08-31 CA CA2771061A patent/CA2771061C/en active Active
- 2010-08-31 PL PL10754594T patent/PL2470520T3/en unknown
- 2010-08-31 GE GEAP201012642A patent/GEP20146080B/en unknown
- 2010-08-31 UA UAA201202432A patent/UA109260C2/en unknown
-
2012
- 2012-01-25 IL IL217729A patent/IL217729A/en active IP Right Grant
- 2012-01-27 CO CO12013015A patent/CO6491096A2/en active IP Right Grant
- 2012-01-31 ZA ZA2012/00770A patent/ZA201200770B/en unknown
- 2012-01-31 TN TNP2012000049A patent/TN2012000049A1/en unknown
- 2012-02-09 MA MA34616A patent/MA35674B1/en unknown
- 2012-02-28 CL CL2012000516A patent/CL2012000516A1/en unknown
- 2012-11-02 HK HK12111043.0A patent/HK1170724A1/en not_active IP Right Cessation
-
2013
- 2013-09-06 HR HRP20130832AT patent/HRP20130832T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089497A (en) * | 1990-09-20 | 1992-02-18 | Warner-Lambert Company | Substituted piperazines as central nervous system agents |
US20050197343A1 (en) * | 2002-07-04 | 2005-09-08 | Peter Gmeiner | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
EP1683790A1 (en) * | 2005-01-24 | 2006-07-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
WO2008009741A1 (en) * | 2006-07-21 | 2008-01-24 | Pierre Fabre Medicament | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same |
Non-Patent Citations (3)
Title |
---|
BUTINI S ET AL: "Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine d3 and serotonin 5-HT 1A and 5-HT2A receptors: Design, synthesis, and effects on behavior", JOURNAL OF MEDICINAL CHEMISTRY 20090108 AMERICAN CHEMICAL SOCIETY USA, vol. 52, no. 1, 8 January 2009 (2009-01-08), pages 151 - 169, XP002560920, ISSN: 0022-2623 * |
HACKLING ANNEKE ET AL: "N-(.omega.-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 46, no. 18, 1 January 2003 (2003-01-01), pages 3883 - 3899, XP002420971, ISSN: 0022-2623 * |
MICHELI F ET AL: "Selective dopamine D3 receptor antagonists. A decade of progress: 1997-2007", EXPERT OPINION ON THERAPEUTIC PATENTS 200808 GB, vol. 18, no. 8, August 2008 (2008-08-01), pages 821 - 840, XP002560921, ISSN: 1354-3776 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957088B2 (en) | 2008-08-05 | 2015-02-17 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
US8969568B2 (en) | 2010-01-29 | 2015-03-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted naphthyridines and their use as medicaments |
US9187478B2 (en) | 2010-01-29 | 2015-11-17 | Boehringer Ingellheim International GmbH | Substituted naphthyridines and their use as medicaments |
US9199937B2 (en) | 2011-07-26 | 2015-12-01 | Boehringer Ingelheim International Gmbh | Substituted quinolines and their use as medicaments |
US10028948B2 (en) | 2013-12-13 | 2018-07-24 | Pierre Fabre Medicament | Chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder |
WO2019086661A1 (en) | 2017-11-03 | 2019-05-09 | Pierre Fabre Medicament | Treatment of schizophrenia |
KR20200083978A (en) | 2017-11-03 | 2020-07-09 | 피에르 파브르 메디카먼트 | Treatment of schizophrenia |
US10842789B2 (en) | 2017-11-03 | 2020-11-24 | Pierre Fabre Medicament | Treatment of schizophrenia |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2470520B1 (en) | Chromone derivatives, a process for their preparation and their therapeutic applications | |
KR100903713B1 (en) | Chromone Derivatives Useful as Vanilloid Antagonists | |
KR20080008378A (en) | Chromane and chromene derivatives and uses thereof | |
SK2862000A3 (en) | Substituted chroman derivatives | |
CA2740262C (en) | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands | |
US20100029682A1 (en) | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same | |
JP5447380B2 (en) | Tricyclic heterocyclic derivatives | |
JPS63277671A (en) | 3-amino-dihydro-(1)-benzopyrane and benzothiopyrane | |
JP2002504549A (en) | Benzylpiperazinyl- and benzylpiperidinylethanone derivatives, their preparation and their use as dopamine D4 receptor antagonists | |
JPH10237071A (en) | New 2-aminoindane compound, its production and pharmaceutical composition containing the same | |
AU2746902A (en) | New indenoindolone compounds, a process for their preparation and pharmaceutical compositions containing them | |
WO1995025731A1 (en) | NOVEL 3-(φ-(4-BENZOYLPIPERIDINO)ALKYL)-4H-BENZOPYRAN-4-ONES, PREPARATION AND THERAPEUTICAL USE THEREOF | |
CZ2000948A3 (en) | Substituted chroman derivatives | |
CZ2000947A3 (en) | Substituted chroman derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080038431.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10754594 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 217729 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12012500173 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010290871 Country of ref document: AU Ref document number: 12013015 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010754594 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2771061 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2010290871 Country of ref document: AU Date of ref document: 20100831 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1562/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/002543 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20127005385 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13393542 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201000862 Country of ref document: TH Ref document number: 2012527432 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12642 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201202432 Country of ref document: UA Ref document number: 2012106743 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012003741 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012003741 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120217 |